Stroke Journal

MARCH 4, 2025

Subarachnoid hemorrhage is a critical neurological condition accounting for about 5% of all strokes, and survivors experience long-term cognitive deterioration and increased risk of dementia. These have emerging treatments that offer promise for the mitigation of effects such as inflammation, iron chelation, and microvascular dysfunction.

Hemorrhage 40

Hemorrhage Genetic predisposition Genetic Markers Quality of Life 40

Cardiometabolic Health Congress

APRIL 12, 2024

Introduction: Addressing the Need for Improved LDL Management in the US There is a clear need for innovative treatments to combat cardiovascular disease (CVD). Heart disease remains the leading cause of death for men and women. 80% of heart attacks and strokes linked to CVD are preventable with optimal risk factor management.

Myocardial Infarction 64

Myocardial Infarction Cardiovascular Disease Heart attacks Heart Attack 64

Dr. Malcolm Kendrick

OCTOBER 30, 2024

(2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M Establishing Fuwai-Oxford research centre (2010-ongoing) Merck: £1.1M

Cholesterol 145

Cholesterol Article Research Diet 145